Abliva AB (publ) (NEVPF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -96.54 Million SEK | -8.7% |
| 2022 | -8.1 Million USD | 40.15% |
| 2021 | -13.54 Million USD | -80.27% |
| 2020 | -7.51 Million USD | 12.34% |
| 2019 | -8.57 Million USD | -5.31% |
| 2018 | -8.14 Million SEK | -10.35% |
| 2017 | -7.37 Million SEK | -32.58% |
| 2016 | -5.56 Million SEK | 25.26% |
| 2015 | -7.44 Million SEK | 83.13% |
| 2014 | -44.12 Million SEK | -297.48% |
| 2013 | 22.34 Million SEK | 235.44% |
| 2012 | -16.49 Million SEK | -75.0% |
| 2011 | -9.42 Million SEK | -126.16% |
| 2010 | -4.16 Million SEK | -172.82% |
| 2009 | -1.52 Million SEK | 4.44% |
| 2008 | -1.59 Million SEK | -30.3% |
| 2007 | -1.22 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.38 Million USD | -35.41% |
| 2024 Q1 | -1.77 Million USD | 22.94% |
| 2023 FY | -8.81 Million USD | -8.7% |
| 2023 Q2 | -2.21 Million USD | -33.74% |
| 2023 Q3 | -2.91 Million USD | -31.56% |
| 2023 Q4 | -2.43 Million USD | 16.46% |
| 2023 Q1 | -1.65 Million USD | 10.28% |
| 2022 Q2 | -1.75 Million SEK | 22.96% |
| 2022 Q3 | -2.34 Million USD | -34.15% |
| 2022 Q4 | -1.84 Million USD | 21.42% |
| 2022 FY | -8.1 Million USD | 40.15% |
| 2022 Q1 | -2.27 Million SEK | 44.19% |
| 2021 Q3 | -3.94 Million SEK | -11.54% |
| 2021 Q4 | -4.07 Million SEK | -3.25% |
| 2021 Q1 | -2.43 Million SEK | 81.49% |
| 2021 Q2 | -3.53 Million SEK | -45.12% |
| 2021 FY | -13.54 Million USD | -80.27% |
| 2020 Q3 | -10.07 Million SEK | 50.41% |
| 2020 Q4 | -13.16 Million SEK | -30.77% |
| 2020 FY | -7.51 Million USD | 12.34% |
| 2020 Q1 | -16.52 Million SEK | 39.29% |
| 2020 Q2 | -20.3 Million SEK | -22.85% |
| 2019 Q2 | -20.75 Million SEK | -50.31% |
| 2019 FY | -8.57 Million USD | -5.31% |
| 2019 Q1 | -13.8 Million SEK | 31.4% |
| 2019 Q3 | -15.28 Million SEK | 26.35% |
| 2019 Q4 | -27.22 Million SEK | -78.09% |
| 2018 Q1 | -12.99 Million SEK | 12.92% |
| 2018 Q2 | -25.16 Million SEK | -93.66% |
| 2018 Q3 | -15.07 Million SEK | 40.09% |
| 2018 Q4 | -20.13 Million SEK | -33.53% |
| 2018 FY | -8.14 Million SEK | -10.35% |
| 2017 Q4 | -14.92 Million SEK | -16.63% |
| 2017 Q3 | -12.79 Million SEK | 42.23% |
| 2017 Q2 | -22.14 Million SEK | -4.3% |
| 2017 Q1 | -21.23 Million SEK | -42.85% |
| 2017 FY | -7.37 Million SEK | -32.58% |
| 2016 Q2 | -12.11 Million SEK | -10.8% |
| 2016 Q1 | -10.93 Million SEK | -49.18% |
| 2016 Q3 | -34.19 Million SEK | -182.12% |
| 2016 FY | -5.56 Million SEK | 25.26% |
| 2016 Q4 | -14.86 Million SEK | 56.53% |
| 2015 Q1 | -14.71 Million SEK | 13.38% |
| 2015 Q3 | -54.05 Million SEK | -252.73% |
| 2015 Q4 | -7.33 Million SEK | 86.44% |
| 2015 Q2 | -15.32 Million SEK | -4.12% |
| 2015 FY | -7.44 Million SEK | 83.13% |
| 2014 Q4 | -16.99 Million SEK | -341.9% |
| 2014 FY | -44.12 Million SEK | -297.48% |
| 2014 Q1 | -9.86 Million SEK | -206.18% |
| 2014 Q2 | -14.09 Million SEK | -42.95% |
| 2014 Q3 | -3.84 Million SEK | 72.72% |
| 2013 Q1 | -4.86 Million SEK | 15.35% |
| 2013 FY | 22.34 Million SEK | 235.44% |
| 2013 Q4 | 9.28 Million SEK | 239.2% |
| 2013 Q3 | -6.67 Million SEK | -337.16% |
| 2013 Q2 | -1.52 Million SEK | 68.62% |
| 2012 Q2 | -4.13 Million SEK | -44.61% |
| 2012 Q1 | -2.85 Million SEK | -11.1% |
| 2012 FY | -16.49 Million SEK | -75.0% |
| 2012 Q4 | -5.74 Million SEK | -38.1% |
| 2012 Q3 | -4.16 Million SEK | -0.73% |
| 2011 Q4 | -2.57 Million SEK | -5.23% |
| 2011 FY | -9.42 Million SEK | -126.16% |
| 2011 Q2 | -3.16 Million SEK | -112.79% |
| 2011 Q1 | -1.48 Million SEK | -11.22% |
| 2011 Q3 | -2.44 Million SEK | 22.74% |
| 2010 Q1 | -535.14 Thousand SEK | -9.5% |
| 2010 FY | -4.16 Million SEK | -172.82% |
| 2010 Q3 | -1.45 Million SEK | -72.75% |
| 2010 Q2 | -842.31 Thousand SEK | -57.4% |
| 2010 Q4 | -1.33 Million SEK | 8.18% |
| 2009 FY | -1.52 Million SEK | 4.44% |
| 2009 Q2 | -415.31 Thousand SEK | -16.89% |
| 2009 Q1 | -355.29 Thousand SEK | 0.0% |
| 2009 Q3 | 321.65 Thousand SEK | 177.45% |
| 2009 Q4 | -488.69 Thousand SEK | -251.93% |
| 2008 FY | -1.59 Million SEK | -30.3% |
| 2007 FY | -1.22 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6786.492% |
| CSL Limited | 3.7 Billion USD | 102.608% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -34.494% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 2064.43% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -36788.96% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -440.976% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 217.954% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -6185.477% |
| Mesoblast Limited | -84.14 Million USD | -14.737% |
| Marizyme, Inc. | -34.08 Million USD | -183.244% |
| Genus plc | 6.4 Million USD | 1608.563% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1091.002% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -10266.123% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1056.263% |
| ContraFect Corporation | -56.88 Million USD | -69.713% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -2019.732% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -38.67 Million USD | -149.662% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -3409.766% |
| MultiCell Technologies, Inc. | -722.81 USD | -13357213.817% |
| Accustem Sciences Inc. | -3.74 Million USD | -2477.074% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -63.668% |
| EV Biologics, Inc. | -483.06 Thousand USD | -19886.668% |
| Q BioMed Inc. | -3.44 Million USD | -2702.053% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 2827.345% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -3574.489% |
| Biomind Labs Inc. | -1 Million USD | -9462.967% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1352.283% |
| Skye Bioscience, Inc. | -13.67 Million USD | -606.184% |
| SQZ Biotechnologies Company | -75.82 Million USD | -27.33% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -322242.415% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1813.933% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -3287.047% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -508.378% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -24683.223% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -1878.628% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -4760.258% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -4895.731% |
| GB Sciences, Inc. | -1.42 Million USD | -6696.719% |
| Alpha Cognition Inc. | -9.7 Million USD | -894.766% |
| argenx SE | -425.04 Million USD | 77.285% |
| HST Global, Inc. | -140.9 Thousand USD | -68418.952% |
| Halberd Corporation | -75.05 Thousand USD | -128544.903% |
| Enzolytics Inc. | -2.14 Million USD | -4393.112% |
| Resverlogix Corp. | -12.74 Million USD | -657.299% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -2947.337% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -73.935% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -75.63% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -9147.893% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -3227.807% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -3207.068% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -5078.586% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -6013.128% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -2735.495% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1542.548% |
| ONE Bio Corp. | 13.68 Million USD | 805.68% |
| Zenith Capital Corp. | -8.94 Million USD | -979.593% |
| Genscript Biotech Corporation | -415.79 Million USD | 76.78% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -554104.695% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -3832.201% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -56193.079% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4715.945% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -8482.762% |
| Agentix Corp. | -1.37 Million USD | -6938.278% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.04 Million USD | -3075.66% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -9711.26% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -7586.943% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1141.141% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -53098.887% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7129.726% |
| LadRx Corporation | -3.82 Million USD | -2425.038% |
| Cell Source, Inc. | -4.32 Million USD | -2132.145% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -23137.757% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -13954.589% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -13954.589% |
| NovAccess Global Inc. | -2.46 Million USD | -3813.96% |
| Affymax, Inc. | -15.04 Million USD | -541.685% |
| Itoco Inc. | -919.14 Thousand USD | -10404.167% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2177.928% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -8528.061% |
| CytoDyn Inc. | -18.05 Million USD | -434.655% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -383483.631% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -43769.901% |
| Qrons Inc. | -643.67 Thousand USD | -14899.448% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -16996.523% |
| SYBLEU INC | -149.18 Thousand USD | -64619.131% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -4229.742% |
| Rebus Holdings, Inc. | -664 Thousand USD | -14440.361% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -5215.583% |
| Mobile Lads Corp. | -554.55 Thousand USD | -17310.152% |
| International Stem Cell Corporation | -663 Thousand USD | -14462.293% |
| Bioxytran, Inc. | -3.82 Million USD | -2427.337% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -183311.854% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -474570.6% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -166.222% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -5867.12% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -13020.876% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -3003.439% |
| Neutra Corp. | -229.48 Thousand USD | -41971.412% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -450.476% |
| PureTech Health plc | -146.19 Million USD | 33.961% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -349.246% |
| IXICO plc | -1.43 Million USD | -6618.72% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -917.258% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 20.736% |
| CSL Limited | 3.81 Billion USD | 102.533% |
| Cellectis S.A. | -108.85 Million USD | 11.308% |